Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

The membrane-associated E3 ubiquitin ligase MARCH3 downregulates the IL-6 receptor and suppresses colitis-associated carcinogenesis

Cellular & Molecular Immunology volume 18, pages 2648–2659 (2021)Cite this article

Subjects

Abstract

The IL-6-STAT3 axis is critically involved in inflammation-associated carcinogenesis (IAC). How this axis is regulated to modulate IAC remains unknown. Here, we show that the plasma membrane-associated E3 ubiquitin ligase MARCH3 negatively regulates STAT3 activation triggered by IL-6, as well as another IL-6 subfamily member, Oncostatin M (OSM). MARCH3 is associated with the IL-6 receptor α-chain (IL-6Rα) and its coreceptor gp130. Biochemical experiments indicated that MARCH3 mediates the polyubiquitination of IL-6Rα at K401 and gp130 at K849 following IL-6 stimulation, leading to their translocation to and degradation in lysosomes. MARCH3 deficiency increases IL-6- and OSM-triggered activation of STAT3 and induction of downstream effector genes in various cell types. MARCH3 deficiency enhances dextran sulfate sodium (DSS)-induced STAT3 activation, increases the expression of inflammatory cytokines, and exacerbates colitis, as well as azoxymethane (AOM)/DSS-induced colitis-associated cancer in mice. In addition, MARCH3 is downregulated in human colorectal cancer tissues and associated with poor survival across different cancer types. Our findings suggest that MARCH3 is a pivotal negative regulator of IL-6-induced STAT3 activation, inflammation, and inflammation-associated carcinogenesis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Murakami M, Kamimura D, Hirano T. Pleiotropy and specificity: insights from the interleukin 6 family of cytokines. Immunity. 2019;50:812–31.

    Article  CAS  Google Scholar 

  2. Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol 2015;16:448–57.

    Article  CAS  Google Scholar 

  3. Guschin D, Rogers N, Briscoe J, Witthuhn B, Watling D, Horn F, et al. A major role for the protein tyrosine kinase JAK1 in the JAK/STAT signal transduction pathway in response to interleukin-6. EMBO J. 1995;14:1421–9.

    Article  CAS  Google Scholar 

  4. Zhong Z, Wen Z, Darnell JE Jr. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science. 1994;264:95–98.

    Article  CAS  Google Scholar 

  5. Levy DE, Darnell JE Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002;3:651–62.

    Article  CAS  Google Scholar 

  6. Yu H, Lee H, Herrmann A, Buettner R, Jove R. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer. 2014;14:736–46.

    Article  CAS  Google Scholar 

  7. Stark, GR, Cheon, H, Wang, Y. Responses to cytokines and interferons that depend upon JAKs and STATs. Cold Spring Harb Perspect Biol. 2018;10:a028555 (2018).

  8. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9:798–809.

    Article  CAS  Google Scholar 

  9. Kang S, Tanaka T, Narazaki M, Kishimoto T. Targeting interleukin-6 signaling in clinic. Immunity. 2019;50:1007–23.

    Article  CAS  Google Scholar 

  10. Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, et al. A family of cytokine-inducible inhibitors of signalling. Nature. 1997;387:917–21.

    Article  CAS  Google Scholar 

  11. Zhang HX, Xu ZS, Lin H, Li M, Xia T, Cui K, et al. TRIM27 mediates STAT3 activation at retromer-positive structures to promote colitis and colitis-associated carcinogenesis. Nat Commun 2018;9:3441.

    Article  Google Scholar 

  12. Xu ZS, Zhang HX, Li WW, Ran Y, Liu TT, Xiong MG, et al. FAM64A positively regulates STAT3 activity to promote Th17 differentiation and colitis-associated carcinogenesis. Proc Natl Acad Sci USA. 2019;116:10447–52.

    Article  CAS  Google Scholar 

  13. Dittrich E, Haft CR, Muys L, Heinrich PC, Graeve L. A di-leucine motif and an upstream serine in the interleukin-6 (IL-6) signal transducer gp130 mediate ligand-induced endocytosis and down-regulation of the IL-6 receptor. J Biol Chem 1996;271:5487–94.

    Article  CAS  Google Scholar 

  14. Zohlnhöfer D, Graeve L, Rose-John S, Schooltink H, Dittrich E, Heinrich PC. The hepatic interleukin-6 receptor. Down-regulation of the interleukin-6 binding subunit (gp80) by its ligand. FEBS Lett 1992;306:219–22.

    Article  Google Scholar 

  15. Lin H, Li S, Shu HB. The membrane-associated MARCH E3 ligase family: emerging roles in immune regulation. Front Immunol 2019;10:1751.

    Article  CAS  Google Scholar 

  16. Liu H, Mintern JD, Villadangos JA. MARCH ligases in immunity. Curr Opin Immunol 2019;58:38–43.

    Article  CAS  Google Scholar 

  17. Lin H, Gao D, Hu MM, Zhang M, Wu XX, Feng L, et al. MARCH3 attenuates IL-1beta-triggered inflammation by mediating K48-linked polyubiquitination and degradation of IL-1RI. Proc Natl Acad Sci USA. 2018;115:12483–8.

    Article  CAS  Google Scholar 

  18. Harroch S, Revel M, Chebath J. Induction by interleukin-6 of interferon regulatory factor 1 (IRF-1) gene expression through the palindromic interferon response element pIRE and cell type-dependent control of IRF-1 binding to DNA. EMBO J. 1994;13:1942–9.

    Article  CAS  Google Scholar 

  19. Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 2005;5:375–86.

    Article  CAS  Google Scholar 

  20. Fukuda H, Nakamura N, Hirose S. MARCH-III Is a novel component of endosomes with properties similar to those of MARCH-II. J Biochem. 2006;139:137–45.

    Article  CAS  Google Scholar 

  21. Babon JJ, Stockwell D, DiRago L, Zhang JG, Laktyushin A, Villadangos J, et al. Membrane-associated RING-CH (MARCH) proteins down-regulate cell surface expression of the interleukin-6 receptor alpha chain (IL6Ralpha). Biochem J. 2019;476:2869–82.

    Article  CAS  Google Scholar 

  22. Garcia-Barcena C, Osinalde N, Ramirez J, Mayor U. How to inactivate human ubiquitin E3 ligases by mutation. Front Cell Dev Biol 2020;8:39.

    Article  Google Scholar 

  23. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J. 1998;334:297–314.

    Article  CAS  Google Scholar 

  24. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004;118:285–96.

    Article  CAS  Google Scholar 

  25. Cui K, Liu C, Li X, Zhang Q, Li Y. Comprehensive characterization of the rRNA metabolism-related genes in human cancer. Oncogene. 2020;39:786–800.

    Article  CAS  Google Scholar 

  26. Hirata H, Sugimachi K, Komatsu H, Ueda M, Masuda T, Uchi R, et al. Decreased expression of fructose-1,6-bisphosphatase associates with glucose metabolism and tumor progression in hepatocellular carcinoma. Cancer Res. 2016;76:3265–76.

    Article  CAS  Google Scholar 

  27. Jones SA, Jenkins BJ. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol. 2018;18:773–89.

    Article  CAS  Google Scholar 

  28. Tanaka Y, Tanaka N, Saeki Y, Tanaka K, Murakami M, Hirano T, et al. c-Cbl-dependent monoubiquitination and lysosomal degradation of gp130. Mol Cell Biol 2008;28:4805–18.

    Article  CAS  Google Scholar 

  29. Lei CQ, Zhong B, Zhang Y, Zhang J, Wang S, Shu HB. Glycogen synthase kinase 3beta regulates IRF3 transcription factor-mediated antiviral response via activation of the kinase TBK1. Immunity. 2010;33:878–89.

    Article  CAS  Google Scholar 

  30. Sanjana NE, Shalem O, Zhang F. Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods. 2014;11:783–4.

    Article  CAS  Google Scholar 

  31. Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelson T, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2014;343:84–87.

    Article  CAS  Google Scholar 

  32. Luo WW, Li S, Li C, Lian H, Yang Q, Zhong B, et al. iRhom2 is essential for innate immunity to DNA viruses by mediating trafficking and stability of the adaptor STING. Nat Immunol 2016;17:1057–66.

    Article  CAS  Google Scholar 

  33. Erben U, Loddenkemper C, Doerfel K, Spieckermann S, Haller D, Heimesaat MM, et al. A guide to histomorphological evaluation of intestinal inflammation in mouse models. Int J Clin Exp Pathol 2014;7:4557–76.

    PubMed  PubMed Central  Google Scholar 

  34. Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell. 2018;173:400–16 e411.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank members of our laboratory for technical help and discussions. This work was supported by grants from the National Key R&D Program of China (2017YFA0505800), the National Natural Science Foundation of China (31630045, 31830024, 31900556, and 32070775), the CAMS Innovation Fund for Medical Sciences (2019-I2M-5-071), the National Postdoctoral Program for Innovative Talents (BX20190255) and the China Postdoctoral Science Foundation (2019M662706).

Author information

Authors and Affiliations

  1. Department of Infectious Diseases, Zhongnan Hospital of Wuhan University; Medical Research Institute; Frontier Science Center for Immunology and Metabolism; Research Unit of Innate Immune and Inflammatory Diseases, Chinese Academy of Medical Sciences; Wuhan University, Wuhan, 430071, China

    Heng Lin, Lu Feng, Lin-Wen Zeng, Deng Gao, Long-Xiang Zhang, Wen-Hua Xu, Yu-Hao Sun, Hong-Bing Shu & Shu Li

  2. Wuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi, 214062, Jiangsu, China

    Kai-Sa Cui

Authors
  1. Heng Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lu Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kai-Sa Cui
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lin-Wen Zeng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Deng Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Long-Xiang Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Wen-Hua Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yu-Hao Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hong-Bing Shu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Shu Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

H-BS, SL, and HL conceived and designed the study. HL, LF, DG, L-XZ, W-HX, L-WZ, and Y-HS performed the experiments. H-BS, HL, and SL analyzed the data. K-SC performed bioinformatics data analysis and visualization. H-BS, SL, and HL wrote the manuscript.

Corresponding authors

Correspondence to Hong-Bing Shu or Shu Li.

Ethics declarations

Competing interests

The authors declare no competing interests.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lin, H., Feng, L., Cui, KS. et al. The membrane-associated E3 ubiquitin ligase MARCH3 downregulates the IL-6 receptor and suppresses colitis-associated carcinogenesis. Cell Mol Immunol 18, 2648–2659 (2021). https://doi.org/10.1038/s41423-021-00799-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41423-021-00799-1

Keywords

Search

Advanced search

Quick links